Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Illumina, Inc. (ILMN) vs Lumen Technologies Inc (LUMN) Price & Performance

Illumina, Inc.Trade
Lumen Technologies IncTrade

Price performance (Past 24H)

Key statistics

Illumina, Inc. vs Lumen Technologies Inc — how do they compare? Illumina, Inc. trades at $191.5 (market cap $29.12B), while Lumen Technologies Inc trades at $6.31 (market cap $6.58B). The key difference: Illumina, Inc. is far larger — about 4.4× Lumen Technologies Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals.

ILMNLUMN
Market Cap
$29.12B$6.58B
Sector
HealthMedia
52-Week High
$205.10$11.83
52-Week Low
$91.00$3.95
Enterprise Value
$30.48B$18.20B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illumina, Inc.

Illumina (ILMN) trades at $192.57, up 0.4% on the day, with a bearish technical signal but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.31 exceeding expectations. Revenue remains stable around $4.3B, and profitability has improved significantly, with a net income margin of 19.57% in 2025. The company maintains robust cash flow from operations of $1.08B in 2025.

The outlook is mixed; strong fundamentals and analyst buy ratings support upside to the $201.58 consensus target, but technical weakness and high valuation ratios pose near-term risks. Key opportunities include sustained earnings beats and AI initiatives, while risks involve competitive pressures and execution challenges in a volatile market.

Lumen Technologies Inc

LUMN stock trades at $6.375, down 3.99% today, amid a bearish technical signal and mixed earnings. The company reported a Q2 2026 loss of $0.07 per share, beating estimates, but revenue declined 9.3% year-over-year. Strategic revenues grew 14.1%, highlighting its digital transformation. CEO Kathleen Johnson purchased 100,000 shares on August 6, 2026, signaling insider confidence. Net cash flow was negative $886 million in 2025, though 2026 projections show improvement. The stock faces headwinds from high debt and legacy revenue declines.

LUMN offers a high-risk opportunity with a low P/S ratio of 0.54 and analyst consensus price target of $7.67, implying potential upside. However, persistent net losses, negative ROE of -78.94%, and $17.49 billion in long-term debt pose significant risks. Investors should weigh the digital growth potential against financial instability and cautious analyst sentiment, with 60.71% holding ratings.

Returns comparison

Trailing returns across standard periods

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN

About Lumen Technologies Inc

With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.

Read more on LUMN